Maiwald Magazine

Maiwald Blog

20 Aug 2024 - Maiwald Blog

Revision of G3/04? – Discussion on the continuation of the appeal by intervener

In opposition appeal proceedings "T1286/23.3.2.04", Board 3.2.4 intends to deviate from decision G 3/04 and thus raises the prospect of a corresponding question being referred...

10 Jul 2024 - Maiwald Blog

Dr. Michaela Weigel-Krusemarck on current developments in formal priority law

In the course of our regular internal attorney seminar,

17 Jun 2024 - Maiwald Blog

One year Unitary Patent and Unified Patent Court in facts and figures

We are already one year into the new European patent and court system – a year of eagerly watching and waiting to see how the Unitary Patent (UP) and the Unified Pa...

All articles

Press Coverage

22 May 2024 - Press Coverage

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK, NY and SOUTH SAN FRANCISCO, CA, May 22, 2024 – Royalty Phar...

9 May 2024 - Press Coverage

Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseases Expands Royalty Pharma’s ...

12 Mar 2024 - Press Coverage

The UPC has become known for its expeditious decision-making processes

The UPC has become known for its expeditious decision-making processes. Just how expeditious it can be, has been shown in a recent case filed with the Munich local division against one of our clients. After a quick review of the claimant’s statement of claim, we infor...

Maiwald in the press

Staff News

Awards

22 Aug 2024 - Award

Who´s Who Legal Rankings 2024

We are delighted that our colleagues Dr. Dirk Büh...

20 Aug 2024 - Award

IAM Strategy 300: The World’s Leading IP Strategists 2024

This year, IAM again recommends eight of our partners: Dr. Eva Dörner,

29 Jun 2024 - Award

IP STARS Top Tier Firm rankings 2024 for patent disputes, protection work and trade mark

We are very delighted to be once again recognized by Managing IP (MIP) as "Top Tier Firm" in the IP STARS Ranking 2024. By being awarded in the categories "Patent prosecution

All awards

Events

Tue.

24 Sep 2024 |Upcoming|Fair

Maiwald will be represented at WindEnergy Hamburg 2024

WindEnergy Hamburg is much more than just a trade fair. It not only covers the entire wind energy value chain, but also offers special expertise with its focus on storage technologies. It also offers you an extensive program and a lot of added value, such as the synergy with the world's leading trade fair for the maritime industry, SMM, which takes place shortly before Win...

Tue.

8 Oct 2024 |Upcoming|External Events

Maiwald is partner of the 3rd Annual Life Science Strategy Summit on IP & Exclusivity from October 8-10 in Munich

We are delighted to support the third annual Life Science Strategy Summit on IP & Exclusivity as a Platinum Partner! This industry-leading life science legal event brings together the leading pharma and biotech experts for three days of practical discussion on the protection of pharm...

Wed.

9 Oct 2024 |Upcoming|External Events

Joint symposium with Oblon in Tokyo (9 Oct. 2024) and Osaka (10 Oct. 2024)

The Oblon and Maiwald firms are pleased to invite you to a complimentary joint international symposium on: U.S. and European Patent Practice: Important Aspects for Practitioners to be presented in two convenient locations / dates: ...

Tue.

15 Oct 2024 |Upcoming|Seminar

Maiwald at the BioM Seminar at Oktober 15 in Martinsried: AI for innovation in the life sciences – opportunities and challenges

The integration of artificial intelligence (AI) into the life sciences is revolutionizing the industry, offering unprecedented opportunities for innovation but also posing significant challenges. Join us for a comprehensive seminar exploring the dynamic intersection of AI and life sciences, with insights from leading experts in the field.

All events

News and Releases

Maiwald Blog

Revision of G3/04? – Discussion on the continuation of the appeal by intervener

Dr. Michaela Weigel-Krusemarck on current developments in formal priority law

One year Unitary Patent and Unified Patent Court in facts and figures

Press Coverage

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

The UPC has become known for its expeditious decision-making processes

Staff News

Maiwald Congratulates on Passing the EQE Examination

Maiwald appoints Dr. Michaela Weigel-Krusemarck and Dr. Andreas Eisele as partners

Dr. Kerstin Wolff and Tobias Matschke promoted to Counsel at Maiwald

Publications

Test Publikation Verknüpfung JP

Wündisch/Zirkel, F&E-Verträge, Handbuch für Wissenschaft und Praxis, 2024 (German only)
Chapter on the Unified Patent Court and Unitary Patent and on the special features of research and development in the pharmaceutical and life sciences sector

Judgment of the Italian Supreme Court on the so-called Bolar Exemption, 2024 (avialable in English)

Awards

Who´s Who Legal Rankings 2024

IAM Strategy 300: The World’s Leading IP Strategists 2024

IP STARS Top Tier Firm rankings 2024 for patent disputes, protection work and trade mark

Events

Maiwald will be represented at WindEnergy Hamburg 2024

Maiwald is partner of the 3rd Annual Life Science Strategy Summit on IP & Exclusivity from October 8-10 in Munich

Joint symposium with Oblon in Tokyo (9 Oct. 2024) and Osaka (10 Oct. 2024)

Maiwald at the BioM Seminar at Oktober 15 in Martinsried: AI for innovation in the life sciences – opportunities and challenges